Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

SAN FRANCISCO -- Older patients' survival in metastatic pancreatic cancer had a significant association with baseline ...

This breakthrough represents a beacon of hope in the fight against pancreatic cancer and other hard-to-treat malignancies.

A research team at Memorial Sloan Kettering Cancer Center (MSK) has made new insights into how the body forms immune cell ...

The new findings show the cancer mortality rate declined by 34% from 1991 to 2022 in the United States, averting ... Experimental Blood Test for Pancreatic Cancer Undergoing Clinical Development ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12 per cent of men diagnosed with pancreatic cancer are alive five years after diagnosis; for women it is 14 per cent.

Researchers from the University of Copenhagen and Rigshospitalet have made significant strides in developing a new treatment for pancreatic cance ...